SCHEMBL1612342

SCHEMBL1612342

CCN(CC)CCCC(C)Nc1c(C)cnc2cc(Cl)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.67
CHRM2 P08172 3/20 0.67
CHRM4 P08173 3/20 0.67
CHRM5 P08912 3/20 0.67
ADRA2A P08913 3/20 0.67
CHRM1 P11229 3/20 0.67
ADRA2B P18089 3/20 0.67
ADRA2C P18825 3/20 0.67
CHRM3 P20309 3/20 0.67
KCNH2 Q12809 3/20 0.67
PRNP P04156 2/20 0.67
MTOR P42345 2/20 0.67
TDP1 Q9NUW8 2/20 0.67
CYP2C19 P33261 2/20 0.67
TMEM97 Q5BJF2 2/20 0.67
SIGMAR1 Q99720 2/20 0.67
ACE2 Q9BYF1 2/20 0.67
APP P05067 1/20 0.67
NQO2 P16083 1/20 0.67
NR4A2 P43354 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16261298 0.86 SLC2A1 (0.63) CYP2D6CHRM2CHRM4CHRM5ADRA2A
SCHEMBL18292453 0.83 LMNA (0.71) CYP2D6CHRM2CHRM4CHRM5ADRA2A
SCHEMBL21982991 0.83 LMNA (0.71) CYP2D6CHRM2CHRM4CHRM5ADRA2A
SCHEMBL18292600 0.83 LMNA (0.71) CYP2D6CHRM2CHRM4CHRM5ADRA2A
SCHEMBL2520992 0.82 CDK1 (0.56) CYP2D6CHRM2CHRM4CHRM5ADRA2A
SCHEMBL21983282 0.82 LMNA (0.68) CYP2D6CHRM2CHRM4CHRM5ADRA2A
Chloroquine SCHEMBL8934 0.80 CHRM2 (1.00) CYP2D6CHRM2CHRM4CHRM5ADRA2A
Chloroquine SCHEMBL8474661 0.80 CHRM2 (1.00) CYP2D6CHRM2CHRM4CHRM5ADRA2A
(R)-Chloroquine SCHEMBL134500 0.80 CHRM2 (1.00) CYP2D6CHRM2CHRM4CHRM5ADRA2A
Chloroquine SCHEMBL8933 0.80 CHRM2 (1.00) CYP2D6CHRM2CHRM4CHRM5ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. 2025-01-30 US claimed
EP-1558254-B1 USE OF 4-AMINOQUINOLINES COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS OF THE EYE RAUT RAJEEV (IN) 2010-12-15 EP claimed
US-20060014786-A1 Opthalmic pharmaceutical compositions and methods for treating ocular inflammation RAUT RAJEEV 2006-01-19 US claimed
US-20030216431-A1 Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation RAUT RAJEEV (IN) 2003-11-20 US claimed
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS KARUNA THERAPEUTICS INC (US) 2026-02-26 US disclosed
EP-4634194-A1 SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2025-10-22 EP disclosed
EP-4634193-A1 SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. (US) 2025-10-22 EP disclosed
US-12421242-B2 Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions Karuna Therapeutics, Inc. (US) 2025-09-23 US disclosed
US-12398119-B2 Piperazine azaspiro derivatives PFIZER INC. (US) 2025-08-26 US disclosed
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. 2025-01-30 US disclosed
US-12144815-B2 Use of aprepitant for treating Alzheimer's disease HOTH THERAPEUTICS, INC. (US) 2024-11-19 US disclosed
US-20240336619-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS Karuna Therapeutics, Inc. 2024-10-10 US disclosed
WO-2010059633-A2 COMPOUNDS FOR TREATING PARASITIC DISEASE OREGON HEALTH & SCIENCE UNIVERSITY (US) 2010-05-27 WO disclosed
WO-2009102570-A2 TREATMENTS FOR NEUROPATHY CHILDREN'S MEDICAL CENTER CORPORATION (US) 2009-08-20 WO disclosed
US-20090203735-A1 TREATMENTS FOR NEUROPATHY NIH-DEITR 2009-08-13 US disclosed
US-7084157-B2 Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation RAUT RAJEEV 2006-08-01 US disclosed
US-20060014786-A1 Opthalmic pharmaceutical compositions and methods for treating ocular inflammation RAUT RAJEEV 2006-01-19 US disclosed
EP-1558254-A2 A PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINOQUINOLINES COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS OF THE EYE, COMPOSITIONS RESULTING THEREFROM Raut, Rajeev (IN) 2005-08-03 EP disclosed
WO-2003097025-A2 A PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINOQUINOLINES COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS OF THE EYE AND COMPOSITIONS RESULTING THEREFROM RAUT RAJEEV (IN) 2003-11-27 WO disclosed
US-20030216431-A1 Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation RAUT RAJEEV (IN) 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12144815-B2 Use of aprepitant for treating Alzheimer's disease TACR1, ACHE, TACR2 CYP2D6 2294/4885CHRM2 158/4885CHRM4 236/4885
US-12398119-B2 Piperazine azaspiro derivatives CHRM1, CHRM2, CHRM5 CYP2D6 360/4885CHRM2 2/4885CHRM4 5/4885
US-20090203735-A1 TREATMENTS FOR NEUROPATHY NGF, BDNF, NTRK2 CYP2D6 3450/4885CHRM2 866/4885CHRM4 1044/4885
US-20060014786-A1 Opthalmic pharmaceutical compositions and methods for treating ocular inflammation AQP4, IL5, CCL11 CYP2D6 1677/4885CHRM2 653/4885CHRM4 369/4885
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE TACR1, ACHE, TACR2 CYP2D6 2294/4885CHRM2 158/4885CHRM4 236/4885
US-20030216431-A1 Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation IL5, IL1B, IL4 CYP2D6 1765/4885CHRM2 1162/4885CHRM4 799/4885
US-20240336619-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CHRM3, CHRM4, CHRM2 CYP2D6 164/4885CHRM2 3/4885CHRM4 2/4885
US-12421242-B2 Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions CHRM3, CHRM4, CHRM2 CYP2D6 164/4885CHRM2 3/4885CHRM4 2/4885
US-20260055116-A1 SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS CHRM3, CHRM2, CHRM1 CYP2D6 99/4885CHRM2 2/4885CHRM4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.